Astrocytic 5-HT2B Receptor as in vitro and in vivo Target of SSRIs

Publisher： Bentham Science Publishers

E-ISSN： 2212-3954|7|3|243-253

ISSN： 1574-8898

Source： Recent Patents on CNS Drug Discovery, Vol.7, Iss.3, 2012-12, pp. : 243-253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5‐HT2B Receptor Antagonists Reduce Nerve Injury‐Induced Tactile Allodynia and Expression of 5‐HT2B Receptors

By  

DRUG DEVELOPMENT RESEARCH, Vol. 76, Iss. 1, 2015-02 ,pp. : 31-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

Astrocytes as a 5-HT2B-Mediated SERT-Independent SSRI Target, Slowly Altering Depression-Associated Genes and Function

By  

Current Signal Transduction Therapy, Vol. 7, Iss. 1, 2012-01 ,pp. : 65-80

Bentham Science Publishers

Access to resources Recommend Favorite

Erythrocyte-protective effect of sarpogrelate hydrochloride (Anplag®), a selective 5-HT2 receptor antagonist: an in vitro study

By Nakamura Ken   Kawahito Koji  

Journal of Artificial Organs, Vol. 13, Iss. 3, 2010-09 ,pp. : 178-181

Springer Publishing Company

Access to resources Recommend Favorite

Platelet serotonin 5-HT2A receptor binding in patients with carcinoid tumor

By Stenman Ulf-Håkan  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 64, Iss. 1, 2004-02 ,pp. : 1-2

Informa Healthcare

Access to resources Recommend Favorite

Platelet serotonin 5-HT2A receptor binding in patients with carcinoid tumor

By Spigset O.   Kristoffersson A.   Mjörndal T.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 64, Iss. 1, 2004-02 ,pp. : 3-8

Informa Healthcare

Access to resources Recommend Favorite